Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Recommendation of "Reduce" by Analysts

Key Points

• Analyst consensus: Nine analysts give Fresenius Medical Care an average recommendation of "Reduce" (4 sell, 5 hold) with a 12‑month average price target of $28, and recent notable moves include downgrades from Jefferies and Goldman Sachs.
• Market valuation & results: Shares opened at $22.36 (down 0.9%) with a market cap of $12.49B and a P/E of 11.71; the company reported EPS of $1.69 and revenue of $5.95B for the last quarter, and its 52‑week range is $20.94–$30.46.
• Institutional activity: Several large investors (notably Pzena Investment Management) increased positions in the third quarter, and hedge funds/institutions own about 8.37% of the stock.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) has earned an average recommendation of "Reduce" from the nine ratings firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $28.00.

FMS has been the topic of a number of analyst reports. Truist Financial set a $28.00 target price on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Weiss Ratings lowered Fresenius Medical Care AG & Co. KGaA from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, March 13th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "strong-buy" rating in a report on Saturday, December 20th. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a "moderate sell" rating to a "strong sell" rating in a research report on Tuesday, February 24th. Finally, The Goldman Sachs Group lowered Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research note on Tuesday, January 20th.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several large investors have recently added to or reduced their stakes in the stock. Factory Mutual Insurance Co. bought a new position in Fresenius Medical Care AG & Co. KGaA in the third quarter worth approximately $1,769,000. Pzena Investment Management LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company's stock worth $390,128,000 after acquiring an additional 153,870 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Fresenius Medical Care AG & Co. KGaA by 8.3% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company's stock valued at $21,491,000 after purchasing an additional 62,700 shares during the period. Todd Asset Management LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 5.2% during the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company's stock valued at $34,319,000 after purchasing an additional 64,311 shares during the period. Finally, Searle & CO. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 246.6% in the 3rd quarter. Searle & CO. now owns 80,725 shares of the company's stock valued at $2,125,000 after purchasing an additional 57,437 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.9%

Shares of FMS opened at $22.36 on Thursday. The company's fifty day simple moving average is $23.08 and its 200-day simple moving average is $24.06. The company has a market cap of $12.49 billion, a P/E ratio of 11.71, a P/E/G ratio of 2.14 and a beta of 0.89. The company has a current ratio of 1.26, a quick ratio of 0.92 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.94 and a twelve month high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported $1.69 EPS for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. The company had revenue of $5.95 billion for the quarter. As a group, analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world's largest integrated provider of products and services for individuals with renal diseases. The company's primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.